RT Journal Article
SR Electronic
T1 Topical application of Urolithin A slows intrinsic skin aging and protects from UVB-mediated photodamage: Findings from Randomized Clinical Trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.16.23291378
DO 10.1101/2023.06.16.23291378
A1 D’Amico, D
A1 Fouassier, AM
A1 Faitg, J
A1 Hennighausen, N
A1 Brandt, M
A1 Konstantopoulos, D
A1 Rinsch, C
A1 Singh, A
YR 2023
UL http://medrxiv.org/content/early/2023/06/20/2023.06.16.23291378.abstract
AB Urolithin A is a gut microbiome derived postbiotic that has been shown to stimulate mitophagy, and improve muscle and mitochondrial health when administered orally to humans. In three separate randomized trials, we have now investigated the effect of topical administration of Urolithin A on skin aging features and on UVB-mediated photodamaged skin. Post-menopausal women with evidence of skin aging such as > Grade 3 wrinkle formation were included in a split-face/arm study design in the first trial (aging study 1; n=48), followed by a second larger trial (aging study 2; n=108) in middle-aged men and women focusing on wrinkle reduction. Healthy participants were included in the placebo-controlled, randomized UVB-induced trial (photo-damage trial; n=22). Participants were randomized to receive topical supplementation with either 0.5% Urolithin A cream or placebo for 8-weeks in a low-dose arm or 1% Urolithin A cream or placebo in the high-dose arm in the aging study 1. In the aging study 2 participants were randomized to receive 1% UA in a day-cream, a night cream and a serum, that were compared to the untreated site. For the photo-damage trial, topical patches containing either 0.5% or 1% UA or placebo cream were applied for 24-hours following UVB irradiation. The primary outcome in the aging study 1 was an impact on biological pathways linked to skin aging in skin biopsies, and an impact on skin barrier function after 8-weeks. Key secondary endpoints were a change in facial wrinkle appearance (crow’s feet area). The aging study 2 focused on wrinkle reduction as a primary outcome. In the UVB-mediated photo-damage study, the primary read-out was the change in erythema after application. Molecular analyses were conducted on skin biopsies and using ex-vivo systems to investigate the mechanism of action mediating skin protective effects of Urolithin A. In the aging study 1, Urolithin A at 1% significantly up-regulated collagen synthesis pathways in human skin biopsies and led to a decrease in wrinkle depth on facial wrinkles. The lower dose had no significant impact. There was no change on skin barrier function with both doses suggesting maintenance of a healthy skin barrier function. In aging study 2, topical application of Urolithin A at the 1% dose in different formulations (day-cream, night cream and serum) led to significant wrinkle reduction compared to the untreated side, confirming the previous findings. Skin hydration was improved significantly as well. In the third trial, investigating impact on photodamaged skin, Urolithin A application led to a significant decrease in UV-induced erythema (∼14%) compared to the untreated area, while placebo and lower dose UA cream’s showed no benefits. Urolithin A topical administration was safe and well-tolerated in all studies. UA also inhibited collagen degrading and pro-inflammatory pathways and up-regulated gene expression of biomarkers linked to induction of mitophagy and autophagy in human skin cells. Taken together, these clinical studies support the topical use of Urolithin A to manage and prolong skin health longevity by acting at the cellular level, supporting collagen structure, reducing wrinkle appearance and protecting against photoaging.The studies are registered in clinicaltrials.gov as: NCT05300984; NCT05473832; NCT05300542Competing Interest StatementThe authors declare the following competing interests: D.D., A.M.F., J.F., C.R. and A.S., are employees of Amazentis SA, who is the sponsor of this clinical study.Clinical TrialNCT05300984; NCT05473832; NCT05300542Funding StatementThis study was funded by Amazentis SAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All the clinical studies were approved by an independent institutional review board (Institutional Review Board (IRB), proderm GmbH, Kiebitzweg 2, D-22869 Schenefeld, Germany).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors